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Supplemental Figure 1: Immunohistochemistry for markers of osteoclasts and osteoblast. Calvaria were 
processed and immunohistologic staining carried out. A) Shown are representative sections of calvaria (from n=5 mice 
per group) stained for RANK (green). B) Shown are representative sections of calvaria (from n=5 mice per group) 
stained for RANKL (green). Nucleus is shown in blue (Dapi). All images were taken at the same magnification 400X. 
Scale bar indicates 50 m. 
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Supplemental Figure 2: MTX increases new bone formation. One week after surgery, XenoLight RediJect Bone 
Probe 680 conjugate was intravenous injected, and the fluorescence image captured. Total flux in photons/sec were 
normalized and expressed as percentage of control to avoid intrinsic changes among animals. Red indicates low signal 
intensity and low rates of new bone formation, while yellow indicates a high signal intensity and high rates of new bone 
formation. Data are expressed as means ±SEM (n=5 per group). ***p<0.001 compared to control (ANOVA). 
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Supplemental Figure 3: Adenosine A2AR activation alters RANKL/OPG mRNA expression ratio in the 
osteoblast. RANKL and Osteoprotegerin (OPG) mRNA expression were analyzed in murine and human BMCs in the 
presence of CGS21680 in alone or with of ZM241385 1µ each. A) RANKL mRNA fold change in murine osteoblast 
precursors after 24 hours challenge with osteogenic media in the presence f CGS21680 alone or with ZM241385 
compared to control (n=6). B) OPG mRNA fold change in murine osteoblast precursors after 24 hours challenge with 
osteogenic media in the presence of CGS21680 alone or with ZM241385 compared to control (n=6). C) RANKL mRNA 
fold change in human osteoblast precursors after 24 hours challenge with osteogenic media in the presence of 
CGS21680 alone or with ZM241385 compared to control (n=6). D) OPG mRNA fold change in human osteoblast 
precursors after 24 hours challenge with osteogenic media in the presenceof CGS21680 alone or with ZM241385 
compared to control (n=6). ***p<0.001 (ANOVA). 
